Benitec Biopharma Inc.
Benitec Biopharma Inc. (Nasdaq: BNTC) is a clinical-stage biotechnology company developing genetic medicines, led by BB-301, an investigational gene therapy for oculopharyngeal muscular dystrophy (OPMD). BB-301 uses the company’s DNA-directed RNA interference and “silence and replace” approach, combining gene… From the company’s description.
In fiscal 2026, Benitec Biopharma Inc. reported a net loss of $45.55M. Operations used $16.52M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Benitec Biopharma Inc. does
In the company’s own words
Benitec Biopharma Inc. (Nasdaq: BNTC) is a clinical-stage biotechnology company developing genetic medicines, led by BB-301, an investigational gene therapy for oculopharyngeal muscular dystrophy (OPMD). BB-301 uses the company’s DNA-directed RNA interference and “silence and replace” approach, combining gene silencing with replacement of the disease-causing gene with a functional version; it is designed for localized administration to pharyngeal muscle. The company’s platform uses viral vectors to deliver genetic constructs intended to produce sustained gene silencing and functional protein expression. Benitec focuses on developing its own candidates and may pursue partnerships or out-license applications outside its areas of focus. It has no reportable business segments described in the business overview. BB-301 is in a Phase 1b/2a clinical study; three participants have been treated in Cohort 2. The candidate has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Benitec’s trademarks include BENITEC BIOPHARMA, BENITEC, and GIVING DISEASE THE SILENT TREATMENT. Its website is www.benitec.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HAYWARD, CA
- Fiscal year end
- June
- CIK
- 1808898
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Benitec Biopharma Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Benitec Biopharma Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Benitec Biopharma Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Benitec Biopharma Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Benitec Biopharma Inc.'s last four quarterly filings that the numbers alone won't show?”